Basilea shares ($BSLN) suffered today after the company disclosed that the FDA isn't backing down from its demands for two pivotal studies of its antibiotic ceftobiprole ahead of any marketing decision. Report
Basilea shares ($BSLN) suffered today after the company disclosed that the FDA isn't backing down from its demands for two pivotal studies of its antibiotic ceftobiprole ahead of any marketing decision. Report